BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9106913)

  • 1. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW
    Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
    Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
    Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects.
    Farde L; Mack RJ; Nyberg S; Halldin C
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S3-7. PubMed ID: 9179638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
    Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
    Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
    Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
    Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
    J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Psychol Med; 1993 Aug; 23(3):791-7. PubMed ID: 7901865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
    Corripio I; Ferreira A; Portella MJ; Pérez V; Escartí MJ; Del Valle Camacho M; Sauras RB; Alonso A; Grasa EM; Carrió I; Catafau AM; Alvarez E
    Psychiatry Res; 2012 Jan; 201(1):73-7. PubMed ID: 22281201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole.
    Nyberg S; Olsson H; Nilsson U; Maehlum E; Halldin C; Farde L
    Psychopharmacology (Berl); 2002 Jun; 162(1):37-41. PubMed ID: 12107615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.